All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
FDA grants fast track designation for LYT-200 in R/R AML and MDS
On January 9, 2025, the U.S. Food and Drug Administration (FDA) granted fast track designation for LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).1 LYT-200 was previously granted orphan drug designation on March 14, 2024.2
LYT-200 is currently being evaluated in a phase I/II trial (NCT05829226) both as monotherapy and in combination with the standard-of-care venetoclax and hypomethylating agents (HMAs) for the treatment of patients with R/R AML/MDS who have received ≥1 line of prior treatment. Data presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 showed that3:
-
Of 22 evaluable patients receiving LYT-200 monotherapy, 59% achieved stable disease or better, with two partial responses.
-
Of 15 evaluable patients receiving LYT-200 in combination with venetoclax/HMA, 80% attained stable disease or better, including two complete responses and one morphologic leukemia free state.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content